pharma · Activated Phosphoinositide 3-Kinase Delta Syndrome · primary immunodeficiency
Pharming Technologies
Pharming Technologies B.V.
Pharming Technologies trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Leiden, NL HQ
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Leiden, NL
- Employees
- 6
- Programs
- 8
- Drugs
- 11
- Patents
- 0
Pharming Technologies clinical trials
Registry index of 8 ClinicalTrials.gov studies linked to Pharming Technologies programs — each row shows trial ID, program name, phase, status, and indication.
Pharming Technologies trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Pharming Technologies.
-
LE 6101 — Phase 1
Clinical update -
LE 5101 — Phase 1
Clinical update -
LE 1102 — Phase 1
Clinical update -
LE 8201 — Phase 2
Clinical update -
LE 7X01 — Phase 2
Clinical update -
LE 3302 — Phase 3
Clinical update -
KL1333 2025-104B — Phase 2
Clinical update -
CDZ173/Leniolisib, CDZ173/Leniolisib — Phase 3
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2024-515489-15-00CTIS ↗
CDZ173/Leniolisib, CDZ173/Leniolisib
Activated Phosphoinositide 3-Kinase Delta Syndrome
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗